Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
02/2003
02/25/2003US6524825 Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
02/25/2003US6524821 Anti-apoptotic compositions comprising the R1 subunit of herpes simplex virus ribonucleotide reductase or its N-terminal portion; and uses thereof
02/25/2003US6524817 DNA encoding a receptor subunit for oncostatin M
02/25/2003US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus
02/25/2003US6524802 Methods of detecting growth differentiation factor-14
02/25/2003US6524592 Oil in water emulsion of white mineral oil, mannitol oleate emulsifier with clostridium and possibly chorynebacterium antigens for prevention of clostridial diseases of sheep (and lambs)
02/25/2003US6524590 Immunoassay
02/25/2003US6524588 Influenza vaccine
02/25/2003US6524587 Inoculation of a Dengue fever virus with nil mortality and subsequent injection of irradiated tumor cells derived from the patient. This therapy will safely reduce the tumor burden by 90-99.9%
02/25/2003US6524586 Providing a naked virus having a capsid; covalently bonding a linker molecule to capsid, wherein polymer is covalently attached to the linker molecule to form a polymer-protected virus for forming viral-physiological structure
02/25/2003US6524584 Saponin compositions and uses thereof
02/25/2003US6524583 Inhibit angiogenesis and induce tumor regression, and have improved safety due to their specificity
02/25/2003US6524582 Methods and compositions for impairing multiplication of HIV-1
02/25/2003CA2099841C Expression of recombinant proteins in attenuated bacteria
02/25/2003CA2019048C Cloth enzyme immunoassay
02/23/2003CA2355348A1 Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
02/21/2003CA2399325A1 Carbohydrate-based whole cell cancer vaccines
02/20/2003WO2003014731A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
02/20/2003WO2003014702A2 Uses of mammalian cytokine; related reagents
02/20/2003WO2003014380A2 Microoroganisms and cells for diagnosis and therapy of tumors
02/20/2003WO2003014335A1 Process for the maturation of dentritic cells and a vaccine
02/20/2003WO2003014326A2 Isolation and mobilization of stem cells expressing vegfr-1
02/20/2003WO2003014322A2 Proteins associated with cell growth, differentiation, and death
02/20/2003WO2003014316A2 Immunomodulatory compositions, formulations, and methods for use thereof
02/20/2003WO2003014301A2 Hprp4s as modifiers of the p53 pathway and methods of use
02/20/2003WO2003014300A2 TRPS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
02/20/2003WO2003014299A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
02/20/2003WO2003014294A2 Tacis and br3 polypeptides and uses thereof
02/20/2003WO2003014161A2 Antigen binding domains from fish
02/20/2003WO2003014154A2 Vaccines against kaposi's sarcoma-associated herpesvirus
02/20/2003WO2003013647A2 Electrodes coated with treating agent and uses thereof
02/20/2003WO2003013603A1 Modulators of p-selectin glycoprotein ligand 1
02/20/2003WO2003013602A1 Inhibitors of her3 activity
02/20/2003WO2003013600A1 Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
02/20/2003WO2003013599A2 Anti-coronavirus vaccine
02/20/2003WO2003013597A1 Sub-unit vaccine for infectious pancreatic necrosis virus
02/20/2003WO2003013596A1 Vaccine
02/20/2003WO2003013594A2 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation
02/20/2003WO2003013593A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder
02/20/2003WO2003013590A1 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
02/20/2003WO2003013577A2 Use of il-18 inhibitors in hypersensitivity disorders
02/20/2003WO2003013575A1 Modulation of leukocyte-endothelial interactions following ischemia
02/20/2003WO2003013485A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma
02/20/2003WO2003013431A2 Compositions and methods for the therapy and diagnosis of breast cancer
02/20/2003WO2003013426A2 Multivalent synthetic vaccine for cancer
02/20/2003WO2003000851A3 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
02/20/2003WO2002099138A3 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
02/20/2003WO2002099062A3 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
02/20/2003WO2002098900A3 Novel human proteins, polynucleotides encoding them and methods of using the same
02/20/2003WO2002098369A3 Mutant forms of cholera holotoxin as an adjuvant
02/20/2003WO2002098360A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
02/20/2003WO2002094862A3 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
02/20/2003WO2002094315A3 Myostatin immunoconjugate and its use for immunisation
02/20/2003WO2002086085A3 Human timp-1 antibodies
02/20/2003WO2002081621A3 Vaccine against the nile fever virus
02/20/2003WO2002079464A3 Viral vectors
02/20/2003WO2002079396A3 Biological carriers for induction of immune responses
02/20/2003WO2002076437A3 Methods for treating neurodegenerative diseases including alzheimer's
02/20/2003WO2002074922A3 Compositions and methods for modulating an immune response
02/20/2003WO2002074331A3 Mutated mhc molecules for use in immune suppression
02/20/2003WO2002069904A3 Cd2 antagonists for treatment of autoimmune or inflammatory disease
02/20/2003WO2002062976A3 Serine proteases
02/20/2003WO2002062298A3 Pro-apoptotic bacterial vaccines to enhance cellular immune responses
02/20/2003WO2002056906A3 Use of mycobacterium w for the treatment of human immunodeficiency virus (hiv) disease infection
02/20/2003WO2002047730A8 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
02/20/2003WO2002045738A3 Vaccine composition containing transforming growth factor alpha
02/20/2003WO2002043705A3 Aerodynamically light vaccine for active pulmonary immunization
02/20/2003WO2002029088A9 Highly expressible genes
02/20/2003WO2002028428A3 Vaccine composition
02/20/2003WO2002026950A3 Transferases
02/20/2003WO2002026193A9 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
02/20/2003WO2002022783A8 Liver gene expression associated with the inhibition of hbv replication or transcription
02/20/2003WO2001072325A9 Methods of blocking tissue destruction by autoreactive t cells
02/20/2003WO2001064949A9 Diagnostics and therapeutics for glaucoma
02/20/2003US20030036645 Breast cancer resistance protein (BCRP) and the DNA which encode it
02/20/2003US20030036639 Immunizing compositions and methods of use
02/20/2003US20030036185 Novel amino acid sequences for human kidney cadherin-like polypeptides
02/20/2003US20030036172 Polypeptide for use in the treatment of cancerous, angiogenesis, inflammatory shock and autoimmune diseases
02/20/2003US20030036171 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
02/20/2003US20030036170 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
02/20/2003US20030036166 ErbB4 receptor-specific neuregulin related ligands and uses therefor
02/20/2003US20030036116 Can be used in combination with other mutagenesis methods
02/20/2003US20030036112 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of nervous system and tumor disorders
02/20/2003US20030036110 Isolation of viral envelope proteins; obtain cells transform with vector containing viral protein, propagate cell, lyse cells, recover envelope proteins
02/20/2003US20030036076 CADs as modifiers of the p53 pathway and methods of use
02/20/2003US20030036056 Inhibitors and target molecule co-localization
02/20/2003US20030035843 Method for processing and preserving collagen-based tissues for transplantation
02/20/2003US20030035814 Cloning Dna; prevention reproduction; gene therapy
02/20/2003US20030035812 Administering vaccine
02/20/2003US20030035811 Method of inactivating microorganisms
02/20/2003US20030035810 Antiallergens
02/20/2003US20030035809 Nucleic acids; veterinary medicine
02/20/2003US20030035808 Complexing heat shock proteins; anticancer agents
02/20/2003US20030035806 Novel meningitis conjugate vaccine
02/20/2003US20030035805 Polysaccharide-protein complex; passivation vaccine
02/20/2003US20030035804 In situ drug delivery
02/20/2003US20030035800 Glycosylated humanized B-cell specific antibodies
02/20/2003US20030035799 Glycosylated antibody
02/20/2003US20030035798 Prevention infections; such as colds, influenza
02/20/2003US20030035797 Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
1 ... 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 ... 1823